FDA approved immune checkpoint inhibitors for bladder cancer include atezolizumab, avelumab, and durvalumab (PD-L1 inhibitors), as well as nivolumab and pembrolizumab (PD-1 inhibitors). This evidence concerns the gene CD274 and urinary bladder carcinoma.